

# Longitudinal analysis reveals high prevalence of Epstein multiple sclerosis

Science

375, 296-301

DOI: [10.1126/science.abj8222](https://doi.org/10.1126/science.abj8222)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epstein-Barr virus and multiple sclerosis. <i>Science</i> , 2022, 375, 264-265.	6.0	68
2	Epstein-Barr virus and MS " a causal link. <i>Nature Reviews Neurology</i> , 2022, , .	4.9	1
3	Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. <i>Nature</i> , 2022, 603, 321-327.	13.7	343
4	Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103561.	0.9	10
5	Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. <i>Science</i> , 2022, 375, 296-301.	6.0	892
6	EBV linked to multiple sclerosis. <i>Nature Reviews Microbiology</i> , 2022, 20, 189-189.	13.6	3
7	Is EBV the cause of multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103636.	0.9	11
9	Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression. <i>Biomedicines</i> , 2022, 10, 387.	1.4	7
11	New Evidence for Epstein-Barr Virus Infection as a Cause of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, 605-606.	1.5	6
12	Linking Epstein-Barr virus infection to multiple sclerosis. <i>Nature Reviews Immunology</i> , 2022, 22, 143-143.	10.6	4
13	Epstein-Barr virus and multiple sclerosis. <i>Nature Reviews Neuroscience</i> , 2022, 23, 133-133.	4.9	2
14	A Final Frontier in Environment-Genome Interactions? Integrated, Multi-Omic Approaches to Predictions of Non-Communicable Disease Risk. <i>Frontiers in Genetics</i> , 2022, 13, 831866.	1.1	5
17	Pandemics disable people " the history lesson that policymakers ignore. <i>Nature</i> , 2022, 602, 383-385.	13.7	9
20	Epstein-Barr virus sparks brain autoimmunity in multiple sclerosis. <i>Nature</i> , 2022, 603, 230-232.	13.7	9
23	Genetic predisposition and the variable course of infectious diseases. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2022, , .	0.6	4
25	Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination. <i>Biomedicines</i> , 2022, 10, 539.	1.4	16
26	Multiple sclerosis: two decades of progress. <i>Lancet Neurology</i> , The, 2022, 21, 211-214.	4.9	16
27	The gut-brain axis goes viral. <i>Cell Host and Microbe</i> , 2022, 30, 283-285.	5.1	5

#	ARTICLE	IF	CITATIONS
28	Targeting Epstein-Barr virus to treat MS. <i>Med</i> , 2022, 3, 159-161.	2.2	1
30	Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells. <i>Glia</i> , 2023, 71, 103-126.	2.5	15
32	How does Epstein-Barr virus trigger MS?. <i>Immunity</i> , 2022, 55, 390-392.	6.6	13
33	Immune Privilege Furnishes a Niche for Latent Infection. <i>Frontiers in Ophthalmology</i> , 2022, 2, .	0.2	3
34	Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3383.	1.8	9
35	Mono a Mano: ZBP1's Love-Hate Relationship with the Kissing Virus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3079.	1.8	5
36	Sclérose en plaques: un virus herpes en cause. , 2022, N° 142, 16-19.		0
37	The link between circulating follicular helper T cells and autoimmunity. <i>Nature Reviews Immunology</i> , 2022, 22, 567-575.	10.6	57
38	Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2022, Volume 12, 61-73.	0.7	8
39	High prevalence of intrathecal IgA synthesis in multiple sclerosis patients. <i>Scientific Reports</i> , 2022, 12, 4247.	1.6	1
40	Antibodies to blood coagulation components are implicated in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103775.	0.9	7
41	The quest to prevent MS and understand other post-viral diseases. <i>Nature</i> , 2022, 603, 784-786.	13.7	2
42	CD8+ T Cell Senescence: Lights and Shadows in Viral Infections, Autoimmune Disorders and Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3374.	1.8	25
44	Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans. <i>Brain</i> , 2023, 146, 645-656.	3.7	15
45	Multiple Sclerosis and Microbiome. <i>Biomolecules</i> , 2022, 12, 433.	1.8	14
46	The Human Myelin Proteome and Sub-Metalloproteome Interaction Map: Relevance to Myelin-Related Neurological Diseases. <i>Brain Sciences</i> , 2022, 12, 434.	1.1	2
47	Kaleidoscope. <i>British Journal of Psychiatry</i> , 2022, 220, 249-250.	1.7	0
48	The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre. <i>Journal of Personalized Medicine</i> , 2022, 12, 591.	1.1	0

#	ARTICLE	IF	CITATIONS
49	Verwechslung zwischen Virus und Gehirn: molekulare Mimikry erkl�rt Verbindung zwischen EBV und MS. DGNeurologie, 0, , 1.	0.0	0
50	Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology, 2022, 18, 289-306.	4.9	27
51	Neurotropic RNA Virus Modulation of Immune Responses within the Central Nervous System. International Journal of Molecular Sciences, 2022, 23, 4018.	1.8	4
52	Myasthenia Gravis: An Acquired Interferonopathy?. Cells, 2022, 11, 1218.	1.8	9
53	Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists. Molecular Psychiatry, 2022, , .	4.1	13
54	Epstein-Barr virus and multiple sclerosis: supporting causality. Lancet Neurology, The, 2022, 21, 300-301.	4.9	8
55	Early clues regarding the pathogenesis of long-COVID. Trends in Immunology, 2022, 43, 268-270.	2.9	79
56	Epstein-Barr virus as a driver of multiple sclerosis. Science Immunology, 2022, 7, eabo7799.	5.6	33
57	Effects of Oxysterols on Immune Cells and Related Diseases. Cells, 2022, 11, 1251.	1.8	15
58	T-cell surveillance of the human brain in health and multiple sclerosis. Seminars in Immunopathology, 2022, 44, 855-867.	2.8	12
59	Major advances in neuroinfectious diseases in the past two decades. Lancet Neurology, The, 2022, 21, 308-310.	4.9	1
60	Natural Killer Cells in Multiple Sclerosis: Entering the Stage. Frontiers in Immunology, 2022, 13, 869447.	2.2	10
61	Inflammation at the crossroads of COVID-19, cognitive deficits and depression. Neuropharmacology, 2022, 209, 109023.	2.0	38
62	Long-term outcomes of pediatric infections: from traditional infectious diseases to long Covid. Future Microbiology, 2022, 17, 551-571.	1.0	62
63	Sociodemographic and clinical characteristics of people with multiple sclerosis and neuro-myelitis optica spectrum disorder in a central northern region of Chile: A prevalence study. Multiple Sclerosis and Related Disorders, 2022, 61, 103750.	0.9	2
64	The dysregulation of autophagy and ER stress induced by HHV-6A infection activates pro-inflammatory pathways and promotes the release of inflammatory cytokines and cathepsin S by CNS cells. Virus Research, 2022, 313, 198726.	1.1	2
66	Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective. Frontiers in Immunology, 2022, 13, 867918.	2.2	7
67	The Conundrum of Lung Disease and Drug Hypersensitivity-like Reactions in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2022, 74, 1122-1131.	2.9	24

#	ARTICLE	IF	CITATIONS
68	Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach. <i>Neurology International</i> , 2022, 14, 368-377.	1.3	5
69	B Cells Specific CpG Induces High IL-10 and IL-6 Expression In Vitro in Neuro-Behçet's Disease. <i>Cells</i> , 2022, 11, 1306.	1.8	3
70	Tissue donations for multiple sclerosis research: current state and suggestions for improvement. <i>Brain Communications</i> , 2022, 4, fcac094.	1.5	4
71	Nonresolving inflammation redux. <i>Immunity</i> , 2022, 55, 592-605.	6.6	35
72	Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2022, 367, 577868.	1.1	2
73	Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis reconsidered. <i>Autoimmunity Reviews</i> , 2022, 21, 103102.	2.5	3
74	Gut microbiome-mediated regulation of neuroinflammation. <i>Current Opinion in Immunology</i> , 2022, 76, 102177.	2.4	30
75	Humoral immune defense of the central nervous system. <i>Current Opinion in Immunology</i> , 2022, 76, 102179.	2.4	3
76	Role of Dendritic Cells in Viral Brain Infections. <i>Frontiers in Immunology</i> , 2022, 13, 862053.	2.2	7
77	Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 866092.	2.2	12
78	Exploring epigenetic reprogramming during central nervous system infection. <i>Immunological Reviews</i> , 2022, 311, 112-129.	2.8	7
79	SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation. <i>Frontiers in Immunology</i> , 2022, 13, 871276.	2.2	13
80	Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis. <i>Journal of Personalized Medicine</i> , 2022, 12, 677.	1.1	3
82	Changes in Brain Neuroimmunology Following Injury and Disease. <i>Frontiers in Integrative Neuroscience</i> , 2022, 16, 894500.	1.0	7
83	Toward identification of personalized immunological profiles in multiple sclerosis. <i>Science Advances</i> , 2022, 8, eabq4849.	4.7	1
84	The enigmatic links between Epstein-Barr virus infection and multiple sclerosis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	4
85	Phage ImmunoPrecipitation Sequencing (PhIP-Seq): The Promise of High Throughput Serology. <i>Pathogens</i> , 2022, 11, 568.	1.2	8
86	Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis. <i>Biomedicines</i> , 2022, 10, 1077.	1.4	6

#	ARTICLE	IF	CITATIONS
87	Onset of multiple sclerosis is preventable – time to act now!. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103875.	0.9	1
88	Multiple sclerosis genetic and non-genetic factors interact through the transient transcriptome. <i>Scientific Reports</i> , 2022, 12, 7536.	1.6	4
90	Guilty by association: Epstein-Barr virus in multiple sclerosis. <i>Nature Medicine</i> , 2022, 28, 904-906.	15.2	15
91	Sphingolipid Players in Multiple Sclerosis: Their Influence on the Initiation and Course of the Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5330.	1.8	11
92	Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1763-1775.	2.0	15
93	Immune checkpoints in T cells during oncogenic herpesvirus infections. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
94	Association between cytomegalovirus infection and tuberculosis disease: A systematic review and meta-analysis of epidemiological studies. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	1
95	Azetidine-2-Carboxylic Acid-Induced Oligodendroglipathy: Relevance to the Pathogenesis of Multiple Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 414-433.	0.9	5
96	The immunology of multiple sclerosis. <i>Nature Reviews Immunology</i> , 2022, 22, 734-750.	10.6	96
97	A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. <i>Science Translational Medicine</i> , 2022, 14, eabf3685.	5.8	34
98	miRNAs in multiple sclerosis: A clinical approach. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103835.	0.9	2
99	Using MS induced pluripotent stem cells to investigate MS aetiology. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103839.	0.9	7
100	Trained immunity in viral infections, Alzheimer's disease and multiple sclerosis: A convergence in type I interferon signalling and IFN $\gamma$ -1a. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166430.	1.8	8
102	Vitamin D as a Risk Factor for Multiple Sclerosis: Immunoregulatory or Neuroprotective?. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	17
103	Involvement of age-associated B cells in EBV-triggered autoimmunity. <i>Immunologic Research</i> , 2022, 70, 546-549.	1.3	5
104	Unexplained post-acute infection syndromes. <i>Nature Medicine</i> , 2022, 28, 911-923.	15.2	231
105	T cell help in the autoreactive germinal center. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13192.	1.3	4
106	Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1697-1709.	1.4	12

#	ARTICLE	IF	CITATIONS
107	Therapeutic Implications of the Microbial Hypothesis of Mental Illness. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 315-351.	0.8	5
110	Î³ T Cells in Brain Homeostasis and Diseases. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	8
111	Current and Future Biomarkers in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5877.	1.8	34
113	Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
114	Neurology of Acute Viral Infections. <i>Neurohospitalist, The</i> , 0, , 194187442211047.	0.3	1
115	Antisense modulation of IL7R splicing to control sIL7R expression in human CD4<sup>+</sup>T cells. <i>Rna</i> , 2022, 28, 1058-1073.	1.6	1
116	Le virus dâ€™Epstein-Barr. <i>Medecine/Sciences</i> , 2022, 38, 422-424.	0.0	1
117	Framework to Segment and Evaluate Multiple Sclerosis Lesion in MRI Slices Using VGG-UNet. <i>Computational Intelligence and Neuroscience</i> , 2022, 2022, 1-10.	1.1	10
118	The Role of Exposomes in the Pathophysiology of Autoimmune Diseases II: Pathogens. <i>Pathophysiology</i> , 2022, 29, 243-280.	1.0	6
119	Frequent intrathecal production of antibodies to the viral capsid antigen of Epstein-Barr virus in patients with central nervous system post-transplant lymphoproliferative disorder. <i>Journal of Neuroimmunology</i> , 2022, 369, 577902.	1.1	1
120	Mycobacterium paratuberculosis zoonosis is a One Health emergency. <i>EcoHealth</i> , 2022, 19, 164-174.	0.9	9
121	Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to â€œoverlapâ€•cases. <i>Journal of Neuroimmunology</i> , 2022, 369, 577904.	1.1	5
122	Alterations in brainstem respiratory centers following peripheral inflammation: A systematic review. <i>Journal of Neuroimmunology</i> , 2022, 369, 577903.	1.1	4
123	Multiple sclerosis and the microbiota. <i>Evolution, Medicine and Public Health</i> , 2022, 10, 277-294.	1.1	5
124	History and prospects of multiple sclerosis treatment. <i>Clinical Neurology</i> , 2022, , .	0.0	0
125	Two Studies Probe and Clarify Factors Linked to â€œLong COVIDâ€™. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2022, 22, 25-26.	0.0	0
126	It Takes Two to Tango: A Review of Oncogenic Virus and Host Microbiome Associated Inflammation in Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 3120.	1.7	7
127	Editorial: Advances in Multiple Sclerosis. <i>Current Opinion in Neurology</i> , 2022, 35, 259-261.	1.8	0

#	ARTICLE	IF	CITATIONS
129	Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept. <i>Cureus</i> , 2022, , .	0.2	6
130	Dental Care and Education Facing Highly Transmissible SARS-CoV-2 Variants: Prospective Biosafety Setting: Prospective, Single-Arm, Single-Center Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7693.	1.2	16
131	What SARS-CoV-2 does to our brains. <i>Immunity</i> , 2022, 55, 1159-1172.	6.6	28
132	Open problems in human trait genetics. <i>Genome Biology</i> , 2022, 23, .	3.8	33
134	Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
135	The Potential for EBV Vaccines to Prevent Multiple Sclerosis. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	17
136	New drugs for multiple sclerosis: new treatment algorithms. <i>Current Opinion in Neurology</i> , 2022, 35, 262-270.	1.8	14
137	Fatty acids role in multiple sclerosis as "metabokines". <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	20
138	Microbiome "Gut Dissociation in the Neonate: Obesity and Coeliac Disease as Examples of Microbiome Function Deficiency Disorder. <i>Gastrointestinal Disorders</i> , 2022, 4, 108-128.	0.4	3
139	Microglial Priming in Infections and Its Risk to Neurodegenerative Diseases. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	9
140	Is post-COVID syndrome an autoimmune disease?. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 653-666.	1.3	18
142	Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
143	SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	129
144	Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge. <i>Cell Reports Medicine</i> , 2022, 3, 100658.	3.3	12
145	Genome-wide analysis of schizophrenia and multiple sclerosis identifies shared genomic loci with mixed direction of effects. <i>Brain, Behavior, and Immunity</i> , 2022, 104, 183-190.	2.0	8
146	VirScan: High-throughput Profiling of Antiviral Antibody Epitopes. <i>Bio-protocol</i> , 2022, 12, .	0.2	7
147	What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?. <i>Neurotherapeutics</i> , 2022, 19, 785-807.	2.1	10
148	Serum Cytokines Predict Neurological Damage in Genetically Diverse Mouse Models. <i>Cells</i> , 2022, 11, 2044.	1.8	2



#	ARTICLE	IF	CITATIONS
149	Oral Dysbiosis and Neurodegenerative Diseases: Correlations and Potential Causations. <i>Microorganisms</i> , 2022, 10, 1326.	1.6	6
150	Early symptoms and diagnosis of multiple sclerosis by the general practitioner. <i>MedicĀna Pro Praxi</i> , 2022, 19, 169-172.	0.0	0
151	Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications. <i>Brain Communications</i> , 2022, 4, .	1.5	30
152	Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	27
153	What causes multiple sclerosis? Getting closer to the answers. <i>Medical Journal of Australia</i> , 0, , .	0.8	0
154	EBV Infection and Its Regulated Metabolic Reprogramming in Nasopharyngeal Tumorigenesis. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	10
155	Age-associated B cells in autoimmune diseases. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	40
156	Predictors of progression from first demyelinating event to clinically definite multiple sclerosis. <i>Brain Communications</i> , 0, , .	1.5	2
157	From the prodromal stage of multiple sclerosis to disease prevention. <i>Nature Reviews Neurology</i> , 2022, 18, 559-572.	4.9	23
158	The Possible Role of Neural Cell Apoptosis in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7584.	1.8	14
159	Resurrecting Epstein-Barr Virus. <i>Pathogens</i> , 2022, 11, 772.	1.2	1
161	Contribution of B cells to cortical damage in multiple sclerosis. <i>Brain</i> , 2022, 145, 3363-3373.	3.7	15
162	Autoimmunity and SARS-CoV-2 infection: Unraveling the link in neurological disorders. <i>European Journal of Immunology</i> , 2022, 52, 1561-1571.	1.6	11
164	Epstein-Barr virus infection: the leading cause of multiple sclerosis. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	2
165	Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	56
166	Assessing clinical utility of machine learning and artificial intelligence approaches to analyze speech recordings in multiple sclerosis: A pilot study. <i>Computers in Biology and Medicine</i> , 2022, 148, 105853.	3.9	10
167	Multiple Sclerosis Management: Current Clinical Approaches to Disease-Modifying Therapy. <i>Current Physical Medicine and Rehabilitation Reports</i> , 0, , .	0.3	0
168	Viral Nucleases from Herpesviruses and Coronavirus in Recombination and Proofreading: Potential Targets for Antiviral Drug Discovery. <i>Viruses</i> , 2022, 14, 1557.	1.5	1

#	ARTICLE	IF	CITATIONS
169	Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. <i>Pharmaceutics</i> , 2022, 14, 1420.	2.0	3
170	EBV as the "gluten of MS" hypothesis provides a rationale for trialing antiviral therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 104007.	0.9	0
171	The role of antiviral CD8+ T cells in cognitive impairment. <i>Current Opinion in Neurobiology</i> , 2022, 76, 102603.	2.0	8
172	Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib. <i>JCI Insight</i> , 2022, 7, .	2.3	12
173	EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	14
174	Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline. <i>Practical Neurology</i> , 2022, 22, 344-357.	0.5	1
175	CD4+ Cytotoxic T Cells Involved in the Development of EBV-Associated Diseases. <i>Pathogens</i> , 2022, 11, 831.	1.2	5
176	Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment. <i>BMJ Neurology Open</i> , 2022, 4, e000271.	0.7	8
177	Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8418.	1.8	8
178	Antibody indices of infectious pathogens from serum and cerebrospinal fluid in patients with schizophrenia spectrum disorders. <i>Fluids and Barriers of the CNS</i> , 2022, 19, .	2.4	4
180	Exploring the Effect of Genetic, Environmental and Lifestyle Factors on Multiple Sclerosis Susceptibility. , 0, , .		0
181	Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4288.	1.0	2
182	Divergent complement system activation in two clinically distinct murine models of multiple sclerosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
183	The role of the complement system in Multiple Sclerosis: A review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
184	The gut microbiome molecular mimicry piece in the multiple sclerosis puzzle. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
185	IFI16 Partners with KAP1 to Maintain Epstein-Barr Virus Latency. <i>Journal of Virology</i> , 2022, 96, .	1.5	9
186	A case of ANCA-associated vasculitis in a 16-year-old female following SARS-COV-2 infection and a systematic review of the literature. <i>Pediatric Rheumatology</i> , 2022, 20, .	0.9	14
187	Investigating EBV biology with Flow-FISH: Implications for EBV-mediated malignancies and the treatment thereof. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 5-7.	1.1	1

#	ARTICLE	IF	CITATIONS
188	Prevalence of chronic comorbidities in people with multiple sclerosis: descriptive study based on administrative data in Tuscany (Central Italy). <i>Neurological Sciences</i> , 2022, 43, 6407-6414.	0.9	3
189	Epstein-Barr Virus (EBV) and Multiple Sclerosis Disease: A Biomedical Diagnosis. <i>Computational Intelligence and Neuroscience</i> , 2022, 2022, 1-4.	1.1	5
191	Infectious mononucleosis is associated with an increased incidence of multiple sclerosis: Results from a cohort study of 32,116 outpatients in Germany. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
192	Deconvolution of B cell receptor repertoire in multiple sclerosis patients revealed a delay in tBreg maturation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
193	Proteomic Profiling of Hypoplastic Lungs Suggests an Underlying Inflammatory Response in the Pathogenesis of Abnormal Lung Development in Congenital Diaphragmatic Hernia. <i>Annals of Surgery</i> , 2023, 278, e411-e421.	2.1	7
194	Pediatric Acquired Demyelinating Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 1104-1130.	0.4	2
195	Epidemiology and Pathophysiology of Multiple Sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 988-1005.	0.4	24
196	Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review. <i>Biomedicines</i> , 2022, 10, 2041.	1.4	1
197	Epstein-Barr virus and multiple sclerosis. <i>Nature Reviews Microbiology</i> , 2023, 21, 51-64.	13.6	151
198	COVID-19 associated myopathy. <i>Current Opinion in Neurology</i> , 2022, 35, 622-628.	1.8	6
199	Editorial: Epigenetic aspects of autoimmune diseases. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
200	Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
201	How does age determine the development of human immune-mediated arthritis?. <i>Nature Reviews Rheumatology</i> , 2022, 18, 501-512.	3.5	4
202	Younger age at multiple sclerosis onset is associated with worse outcomes at age 50. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1112-1119.	0.9	1
203	B cells going viral in the CNS: Dynamics, complexities, and functions of B cells responding to viral encephalitis. <i>Immunological Reviews</i> , 2022, 311, 75-89.	2.8	5
204	High Predictive Value of the Soluble ZEBRA Antigen (Epstein-Barr Virus Trans-Activator Zta) in Transplant Patients with PTLD. <i>Pathogens</i> , 2022, 11, 928.	1.2	3
205	The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
206	NLRP3 inflammasome in neurodegenerative disease. <i>Translational Research</i> , 2023, 252, 21-33.	2.2	25

#	ARTICLE	IF	CITATIONS
207	EBV as the "gluten of MS"™ hypothesis: Bypassing autoimmunity. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 66, 104069.	0.9	0
208	Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 67, 104094.	0.9	14
209	The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104103.	0.9	21
210	The oncogenic gamma herpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) hijack retinoic acid-inducible gene I (RIG-I) facilitating both viral and tumour immune evasion. <i>Tumour Virus Research</i> , 2022, 14, 200246.	1.5	4
211	Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments for Central Nervous System Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10336.	1.8	16
214	G <sub>1</sub> /S Cell Cycle Induction by Epstein-Barr Virus BORF2 Is Mediated by P53 and APOBEC3B. <i>Journal of Virology</i> , 2022, 96, .	1.5	2
215	MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis. <i>Journal of Neuroimmunology</i> , 2022, 371, 577935.	1.1	6
216	Therapeutic approaches to Epstein-Barr virus cancers. <i>Current Opinion in Virology</i> , 2022, 56, 101260.	2.6	7
217	Transcriptomic changes in autophagy-related genes are inversely correlated with inflammation and are associated with multiple sclerosis lesion pathology. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2022, 25, 100510.	1.3	3
218	EBV and multiple sclerosis: Setting the research agenda. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 67, 104158.	0.9	2
219	Revisiting the antiviral theory to explain interferon-beta's effectiveness for relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 67, 104155.	0.9	5
220	When a 17-Year-Old Girl Is Diagnosed with Myalgic Encephalomyelitis: A Case Study from the Swedish Health Care System—A Parent Perspective. <i>Case Reports in Clinical Medicine</i> , 2022, 11, 280-296.	0.1	0
221	Neurofilament light chain and mercury amalgam fillings in monozygotic twins discordant for multiple sclerosis case report. <i>Neuroimmunology Reports</i> , 2022, 2, 100140.	0.2	0
222	The feasibility of an online educational lifestyle program for people with multiple sclerosis: A qualitative analysis of participant semi-structured interviews. <i>Digital Health</i> , 2022, 8, 205520762211237.	0.9	4
223	Neuroinflammation in Multiple Sclerosis. , 2022, , .		0
224	At the Root of 3 "Long" Diseases: Persistent Antigens Inflicting Chronic Damage on the Brain and Other Organs in Gulf War Illness, Long-COVID-19, and Chronic Fatigue Syndrome. <i>Neuroscience Insights</i> , 2022, 17, 263310552211148.	0.9	9
225	Microglia in antiviral immunity of the brain and spinal cord. <i>Seminars in Immunology</i> , 2022, 60, 101650.	2.7	1
227	Toward Precision Phenotyping of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	22

#	ARTICLE	IF	CITATIONS
228	Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases. <i>Pharmaceuticals</i> , 2022, 15, 1077.	1.7	4
229	Time-resolved transcriptomes reveal diverse B cell fate trajectories in the early response to Epstein-Barr virus infection. <i>Cell Reports</i> , 2022, 40, 111286.	2.9	14
230	<i>Drosophila</i> as a Model for Human Viral Neuroinfections. <i>Cells</i> , 2022, 11, 2685.	1.8	2
231	Are Viral Infections Key Inducers of Autoimmune Diseases? Focus on Epstein-Barr Virus. <i>Viruses</i> , 2022, 14, 1900.	1.5	10
232	Declining Epstein-Barr Virus Antibody Prevalence in College Freshmen Strengthens the Rationale for a Prophylactic EBV Vaccine. <i>Vaccines</i> , 2022, 10, 1399.	2.1	2
233	Breastfeeding and Risk of Multiple Sclerosis: A Systematic Review and Meta-Analysis of Observational Studies. <i>Neuroepidemiology</i> , 2022, 56, 391-401.	1.1	2
234	Moyamoya disease emerging as an immune-related angiopathy. <i>Trends in Molecular Medicine</i> , 2022, 28, 939-950.	3.5	22
235	Peptide Microarrays for Studying Autoantibodies in Neurological Disease. <i>Methods in Molecular Biology</i> , 2023, , 17-25.	0.4	5
236	Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
237	Similar Time Trends of Hodgkin Lymphoma, Multiple Sclerosis, and Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2023, 68, 1455-1463.	1.1	2
238	The Immunobiology and Pathogenesis of Celiac Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2023, 18, 47-70.	9.6	34
239	From real-world electronic health record data to real-world results using artificial intelligence. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 306-311.	0.5	24
240	Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
241	Altered Immune Response to the Epstein-Barr Virus as a Prerequisite for Multiple Sclerosis. <i>Cells</i> , 2022, 11, 2757.	1.8	9
242	Transcriptional abnormalities in induced pluripotent stem cell-derived oligodendrocytes of individuals with primary progressive multiple sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 0, 16, .	1.8	2
243	Team victory, yellow helmets for a computational tour de force. <i>Cell</i> , 2022, 185, 3459-3461.	13.5	1
244	Peroxisomal very long-chain fatty acid transport is targeted by herpesviruses and the antiviral host response. <i>Communications Biology</i> , 2022, 5, .	2.0	6
245	Multiple Sclerosis in a Patient With Prior West Nile Encephalitis. <i>Cureus</i> , 2022, , .	0.2	1

#	ARTICLE	IF	CITATIONS
246	The role of virus infections in Sjögren's syndrome. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
247	Training the next generation of Sudanese immunologists: a case for mentorship. <i>Immunology and Cell Biology</i> , 2022, 100, 687-690.	1.0	2
248	Falling down the biological rabbit hole: Epstein-Barr virus, biography, and multiple sclerosis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
249	Evolution of functional antibodies following acute Epstein-Barr virus infection. <i>PLoS Pathogens</i> , 2022, 18, e1010738.	2.1	5
250	Epstein-Barr Virus Detection in the Central Nervous System of HIV-Infected Patients. <i>Pathogens</i> , 2022, 11, 1080.	1.2	2
251	Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
252	Methionine metabolism controls the B cell EBV epigenome and viral latency. <i>Cell Metabolism</i> , 2022, 34, 1280-1297.e9.	7.2	16
253	Whole Exome Sequencing in Multi-Incident Families Identifies Novel Candidate Genes for Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11461.	1.8	3
254	Immunoinformatics Approach to Design Novel Subunit Vaccine against the Epstein-Barr Virus. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	10
255	A shared B-cell clonotype in patients with Interstitial Cystitis/Bladder Pain Syndrome presenting with Hunner lesions. , 2022, , 100015.		1
256	Inhibition of Th1 activation and differentiation by dietary guar gum ameliorates experimental autoimmune encephalomyelitis. <i>Cell Reports</i> , 2022, 40, 111328.	2.9	9
258	Epstein-Barr virus: Biology and clinical disease. <i>Cell</i> , 2022, 185, 3652-3670.	13.5	78
259	Cell-based experimental strategies for myelin repair in multiple sclerosis. <i>Journal of Neuroscience Research</i> , 2023, 101, 86-111.	1.3	0
260	Epstein-Barr virus perpetuates B cell germinal center dynamics and generation of autoimmune-associated phenotypes in vitro. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
262	Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	24
264	ZBP1: A Powerful Innate Immune Sensor and Double-Edged Sword in Host Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10224.	1.8	20
265	Haplotype-specific chromatin looping reveals genetic interactions of regulatory regions modulating gene expression in 8p23.1. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
266	COVID-19 and cellular senescence. <i>Nature Reviews Immunology</i> , 2023, 23, 251-263.	10.6	54

#	ARTICLE	IF	CITATIONS
267	EBV-verified TCRs and multiple sclerosis. <i>Science Immunology</i> , 2022, 7, .	5.6	0
268	Targeting Environmental Risks to Prevent Rheumatic Disease. <i>Rheumatic Disease Clinics of North America</i> , 2022, . .	0.8	0
269	Microbiome epidemiology and association studies in human health. <i>Nature Reviews Genetics</i> , 2023, 24, 109-124.	7.7	17
270	Linking X to MS: Immunity and demyelination on the X-chromosome in MS. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 66, 104190.	0.9	0
271	Epstein-Barr virus, interleukin-10 and multiple sclerosis: A <i>trio</i> . <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
272	Two phases of macrophages: Inducing maturation and death of oligodendrocytes in vitro co-culture. <i>Journal of Neuroscience Methods</i> , 2022, 382, 109723.	1.3	2
273	Comparison of Elecsys and Liaison immunoassays to determine Epstein-Barr virus serological status using further diagnostic approaches to clarify discrepant results. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
274	Epstein-Barr virus infection, B-cell dysfunction and other risk factors converge in gut-associated lymphoid tissue to drive the immunopathogenesis of multiple sclerosis: a hypothesis. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	6
275	Introduction: Trends, Puzzles, and Hopes for the Future of Healthcare. <i>Future of Business and Finance</i> , 2022, , 1-24.	0.3	1
276	A letter to the editor concerning "Geochemistry of multiple sclerosis in Finland". <i>Science of the Total Environment</i> , 2023, 856, 159606.	3.9	1
277	A gene regulatory network approach harmonizes genetic and epigenetic signals and reveals repurposable drug candidates for multiple sclerosis. <i>Human Molecular Genetics</i> , 2023, 32, 998-1009.	1.4	5
278	The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases. <i>Biomedicines</i> , 2022, 10, 2492.	1.4	4
279	An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 675-688.	2.0	9
281	MicroRNA-mediated control of Epstein-Barr virus infection and potential diagnostic and therapeutic implications. <i>Current Opinion in Virology</i> , 2022, 56, 101272.	2.6	5
282	EBV-associated diseases: Current therapeutics and emerging technologies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
283	Thermodynamic and structural characterization of an EBV infected B-cell lymphoma transcriptome. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, .	1.5	2
284	Human cerebral organoids "a new tool for clinical neurology research. <i>Nature Reviews Neurology</i> , 2022, 18, 661-680.	4.9	49
285	Updates and advances in multiple sclerosis neurotherapeutics. <i>Neurodegenerative Disease Management</i> , 2023, 13, 47-70.	1.2	29

#	ARTICLE	IF	CITATIONS
286	Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis. <i>Neurologic Clinics</i> , 2023, 41, 87-106.	0.8	3
287	Theilerâ€™s virus-induced demyelinating disease as an infectious model of progressive multiple sclerosis. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	8
288	Effect of teriflunomide on Epsteinâ€™Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104377.	0.9	3
289	Molecular disease mechanisms of human antineuronal monoclonal autoantibodies. <i>Trends in Molecular Medicine</i> , 2023, 29, 20-34.	3.5	11
290	Association between Epstein-Barr virus serological reactivation and psychological distress: a cross-sectional study of Japanese community-dwelling older adults. <i>Aging</i> , 0, , .	1.4	1
291	How EBV Infects: The Tropism and Underlying Molecular Mechanism for Viral Infection. <i>Viruses</i> , 2022, 14, 2372.	1.5	15
292	Crystal Structures of Epsteinâ€™Barr Virus Bcl-2 Homolog BHRF1 Bound to Bid and Puma BH3 Motif Peptides. <i>Viruses</i> , 2022, 14, 2222.	1.5	1
293	Increased expression of PD-1 in CD8â€™+â€™CD3â€™+â€™T cells correlates with EBV viral load in MS patients. <i>Journal of NeuroVirology</i> , 0, , .	1.0	1
294	A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis. <i>Biomedicines</i> , 2022, 10, 2604.	1.4	6
295	Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition. <i>Immunity</i> , 2022, 55, 2135-2148.e6.	6.6	7
297	Studying the Interactions of U24 from HHV-6 in Order to Further Elucidate Its Potential Role in MS. <i>Viruses</i> , 2022, 14, 2384.	1.5	2
298	Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
299	Single-Cell Analysis to Better Understand the Mechanisms Involved in MS. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12142.	1.8	2
300	The validity of animal models to explore the pathogenic role of the complement system in multiple sclerosis: A review. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	2
302	Autoimmune diseases: the immunological tightrope. <i>The Prescriber</i> , 2022, 33, 19-22.	0.1	1
304	Oncogenic viruses, cancer biology, and innate immunity. <i>Current Opinion in Immunology</i> , 2022, 78, 102253.	2.4	1
307	HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
308	Prior hospitalâ€™based infection and risk of eosinophilic esophagitis in a Swedish nationwide caseâ€™control study. <i>United European Gastroenterology Journal</i> , 2022, 10, 999-1007.	1.6	3



#	ARTICLE	IF	CITATIONS
309	Microbial dysbiosis in the gut drives systemic autoimmune diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	30
310	The industrial genomic revolution: A new era in neuroimmunology. <i>Neuron</i> , 2022, 110, 3429-3443.	3.8	2
311	Siblings reduce multiple sclerosis risk by preventing delayed primary Epstein-Barr virus infection. <i>Brain</i> , 2023, 146, 1993-2002.	3.7	7
312	The biological rabbit hole: Only for the blind. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 67, 104256.	0.9	1
313	Interplay between activation of endogenous retroviruses and inflammation as common pathogenic mechanism in neurological and psychiatric disorders. <i>Brain, Behavior, and Immunity</i> , 2023, 107, 242-252.	2.0	7
314	Ocrelizumab treatment in newly diagnosed multiple sclerosis patients with previous Hodgkin's lymphoma. <i>Neuroimmunology Reports</i> , 2022, 2, 100151.	0.2	0
315	Mapping the Literature on Diet and Multiple Sclerosis: A Data-Driven Approach. <i>Nutrients</i> , 2022, 14, 4820.	1.7	3
317	Increased cytomegalovirus immune responses at disease onset are protective in the long-term prognosis of patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 0, , jnp-2022-330205.	0.9	4
318	Antigenic mimicry – The key to autoimmunity in immune privileged organs. <i>Journal of Autoimmunity</i> , 2023, 137, 102942.	3.0	6
319	A journey with no roadmap – The need for validated criteria of the MS prodrome. <i>Multiple Sclerosis Journal</i> , 2023, 29, 502-504.	1.4	0
321	What do animal models tell us about the role of EBV in the pathogenesis of multiple sclerosis?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
322	COVID-19 and Clinically Isolated Syndrome: Coincidence or Causative Link? A 12-Month Follow-Up Case Report. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 11531.	1.3	1
323	In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim. <i>BMC Medical Informatics and Decision Making</i> , 2023, 22, .	1.5	7
324	Antiviral Innate Immune Responses in Autoimmunity: Receptors, Pathways, and Therapeutic Targeting. <i>Biomedicines</i> , 2022, 10, 2820.	1.4	3
325	Keeping T cell memories in mind. <i>Trends in Immunology</i> , 2022, 43, 1018-1031.	2.9	3
326	MicroRNAs as a possible biomarker in the treatment of multiple sclerosis. <i>IBRO Neuroscience Reports</i> , 2022, 13, 492-499.	0.7	3
327	Peripheral T-Cells, B-Cells, and Monocytes from Multiple Sclerosis Patients Supplemented with High-Dose Vitamin D Show Distinct Changes in Gene Expression Profiles. <i>Nutrients</i> , 2022, 14, 4737.	1.7	6
328	Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14209.	1.8	0

#	ARTICLE	IF	CITATIONS
329	Analysis of herpesvirus infection and genome single nucleotide polymorphism risk factors in multiple sclerosis, Volga federal district, Russia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
330	Chickenpox and multiple sclerosis: A Mendelian randomization study. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	7
331	Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 3915-3927.	2.0	5
332	Epstein-Barr Virus-Induced Genes and Endogenous Retroviruses in Immortalized B Cells from Patients with Multiple Sclerosis. <i>Cells</i> , 2022, 11, 3619.	1.8	5
333	Dynamics of Viral and Host 3D Genome Structure upon Infection. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1515-1526.	0.9	3
335	Socioeconomic and race/ethnic differences in immunosenescence: Evidence from the Health and Retirement Study. <i>Brain, Behavior, and Immunity</i> , 2023, 107, 361-368.	2.0	9
336	The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms?. <i>Autoimmunity Reviews</i> , 2022, , 103237.	2.5	2
338	The Need/Failure to React, Adequately Prioritise and Persevere. , 2022, , 155-191.		0
339	T cells in the brain inflammation. <i>Advances in Immunology</i> , 2023, , 29-58.	1.1	3
340	Comment on "The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging". <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 1624-1625.	0.3	0
341	Multiple sclerosis in 2022: old players, new insights. <i>Lancet Neurology</i> , The, 2023, 22, 19-21.	4.9	0
342	Unaltered T cell responses to common antigens in individuals with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2023, 444, 120510.	0.3	8
343	Arzneimittelversorgung bei Multipler Sklerose. , 2022, , 139-159.		0
344	Family Herpesviridae and neuroinfections: current status and research in progress. <i>Memorias Do Instituto Oswaldo Cruz</i> , 0, 117, .	0.8	9
345	High prevalence of low-allele-fraction somatic mutations in STAT3 in peripheral blood CD8+ cells in multiple sclerosis patients and controls. <i>PLoS ONE</i> , 2022, 17, e0278245.	1.1	2
346	Autoimmune pre-disease. <i>Autoimmunity Reviews</i> , 2023, 22, 103236.	2.5	25
347	Cell-free DNA-based liquid biopsies in neurology. <i>Brain</i> , 2023, 146, 1758-1774.	3.7	19
348	A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus. <i>Virology Journal</i> , 2022, 19, .	1.4	1

#	ARTICLE	IF	CITATIONS
349	Gammaherpesvirus infection drives age-associated B cells toward pathogenicity in EAE and MS. <i>Science Advances</i> , 2022, 8, .	4.7	7
350	Infectious mononucleosis is associated with an increased incidence of <sc>NAFLD</sc>. <i>European Journal of Clinical Investigation</i> , 0, , .	1.7	0
351	The Association between Infectious Mononucleosis and Cancer: A Cohort Study of 24,190 Outpatients in Germany. <i>Cancers</i> , 2022, 14, 5837.	1.7	4
352	The immunomodulatory roles of the gut microbiome in autoimmune diseases of the central nervous system: Multiple sclerosis as a model. <i>Journal of Autoimmunity</i> , 2023, 137, 102957.	3.0	4
353	Comparative Animal Models of Human Viral Infections. <i>Pathogens</i> , 2022, 11, 1395.	1.2	0
354	Epsteinâ€Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14389.	1.8	11
355	A common mechanism links Epsteinâ€Barr virus infections and autoimmune diseases. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	11
356	Increased risk for acute periapical abscesses in multiple sclerosis patients and the possible association with Epstein Barr virus.. <i>Journal of Endodontics</i> , 2022, , .	1.4	1
357	Supplementation with <i>Crocus sativus</i> L. (Saffron) against Placebo in Multiple Sclerosis: A Systematic Review and Synthesis without Meta-Analysis of Randomized Controlled Trials. <i>Dietetics</i> , 2022, 1, 227-241.	0.4	1
358	Better late than never: A unique strategy for late gene transcription in the beta- and gammaherpesviruses. <i>Seminars in Cell and Developmental Biology</i> , 2023, 146, 57-69.	2.3	5
359	Occurrence of multiple respiratory viruses in wastewater in Queensland, Australia: Potential for community disease surveillance. <i>Science of the Total Environment</i> , 2023, 864, 161023.	3.9	35
360	Urgency and necessity of Epstein-Barr virus prophylactic vaccines. <i>Npj Vaccines</i> , 2022, 7, .	2.9	20
362	Hypothesis of a potential BrainBiota and its relation to CNS autoimmune inflammation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
363	Implications of Post-Translational Modifications in Autoimmunity with Emphasis on Citrullination, Homocitrullination and Acetylation for the Pathogenesis, Diagnosis and Prognosis of Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15803.	1.8	7
365	Clinical Neuroimaging in Pediatric Dysimmune Disorders of the Central Nervous System. <i>Seminars in Roentgenology</i> , 2022, , .	0.2	0
366	Tissue specific signature of HHV-6 infection in ME/CFS. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	11
367	MS associated with a broader Epstein-Barr virus specific T-cell receptor repertoire. , 0, , .		0
368	Tissueâ€Targeted Drug Delivery Strategies to Promote Antigenâ€Specific Immune Tolerance. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	4

#	ARTICLE	IF	CITATIONS
369	Comprehensively identifying Long Covid articles with human-in-the-loop machine learning. <i>Patterns</i> , 2023, 4, 100659.	3.1	4
370	Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis. <i>Journal of Neurology</i> , 2023, 270, 1908-1930.	1.8	6
371	Co-Infection of the Epstein-Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus. <i>Viruses</i> , 2022, 14, 2709.	1.5	7
372	Genetic risk factors for ME/CFS identified using combinatorial analysis. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
373	Ces virus qui nous habitent et qui nous visitent : le virome humain. <i>Medecine/Sciences</i> , 2022, 38, 1028-1038.	0.0	0
374	Chronic viral coinfections differentially affect the likelihood of developing long COVID. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	73
375	Chimeric antigen receptor-based therapies beyond cancer. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	2
376	Synapse Dysfunctions in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1639.	1.8	5
377	Potentially toxic elements in the brains of people with multiple sclerosis. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
378	Differential DNA methylation associated with multiple sclerosis and disease modifying treatments in an underrepresented minority population. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
380	The repertoire of CSF antiviral antibodies in patients with neuroinflammatory diseases. <i>Science Advances</i> , 2023, 9, .	4.7	1
381	Sequence similarity between SARS-CoV-2 nucleocapsid and multiple sclerosis-associated proteins provides insight into viral neuropathogenesis following infection. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
382	New insight into Epstein-Barr virus infection using models of stratified epithelium. <i>PLoS Pathogens</i> , 2023, 19, e1011040.	2.1	4
383	Epstein-Barr virus infection mimicking acute appendicitis: a case report. <i>World Journal of Emergency Medicine</i> , 2023, 14, .	0.5	1
384	Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	11
385	Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein-Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1500.	1.8	2
386	Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps. <i>Advanced Science</i> , 2023, 10, .	5.6	8
387	Antigen clearance at the peak of the primary immune response induces experimental autoimmune encephalomyelitis. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	0

#	ARTICLE	IF	CITATIONS
388	Immune dysregulation. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 70-80.	1.5	11
389	How viral infections cause neuronal dysfunction: a focus on the role of microglia and astrocytes. <i>Biochemical Society Transactions</i> , 2023, 51, 259-274.	1.6	3
390	Pre-existing conditions associated with post-acute sequelae of COVID-19. <i>Journal of Autoimmunity</i> , 2023, 135, 102991.	3.0	8
391	B Cells Drive MHC Class II-Restricted CD4 T Cells to Induce Spontaneous Central Nervous System Autoimmunity. <i>Journal of Immunology</i> , 2022, 209, 1880-1891.	0.4	2
392	Is there a role for herpes simplex virus type 1 in multiple sclerosis?. <i>Microbes and Infection</i> , 2023, 25, 105084.	1.0	3
393	Gene-environment interactions and their impact on human health. <i>Genes and Immunity</i> , 2023, 24, 1-11.	2.2	28
394	Shaping the host cell environment with viral noncoding RNAs. <i>Seminars in Cell and Developmental Biology</i> , 2022, , .	2.3	0
395	Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease. <i>Pharmaceutics</i> , 2023, 15, 83.	2.0	6
396	Endogenous Retroviruses as Modulators of Innate Immunity. <i>Pathogens</i> , 2023, 12, 162.	1.2	15
397	Massive health-record review links viral illnesses to brain disease. <i>Nature</i> , 2023, 614, 18-19.	13.7	5
398	Retinoblastoma Protein Is Required for Epstein-Barr Virus Replication in Differentiated Epithelia. <i>Journal of Virology</i> , 2023, 97, .	1.5	2
399	People with Primary Progressive Multiple Sclerosis Have a Lower Number of Central Memory T Cells and HLA-DR+ Tregs. <i>Cells</i> , 2023, 12, 439.	1.8	6
400	Infectious mononucleosis is associated with an increased incidence of Crohn's disease: results from a cohort study of 31 862 outpatients in Germany. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 255-260.	0.8	2
401	Protein Kinase CK2 and Epstein-Barr Virus. <i>Biomedicines</i> , 2023, 11, 358.	1.4	2
402	Virus exposure and neurodegenerative disease risk across national biobanks. <i>Neuron</i> , 2023, 111, 1086-1093.e2.	3.8	87
403	Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 1646-1654.	1.5	11
404	Persistent virus-specific and clonally expanded antibody-secreting cells respond to induced self-antigen in the CNS. <i>Acta Neuropathologica</i> , 2023, 145, 335-355.	3.9	3
405	Cigarette smoking is associated with Herpesviruses in persons with and without serious mental illness. <i>PLoS ONE</i> , 2023, 18, e0280443.	1.1	1

#	ARTICLE	IF	CITATIONS
406	Myelin Basic Protein Fragmentation by Engineered Human Proteasomes with Different Catalytic Phenotypes Revealed Direct Peptide Ligands of MS-Associated and Protective HLA Class I Molecules. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2091.	1.8	0
407	Dual Role of B Cells in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2336.	1.8	7
408	Multiple Sclerosis Is Associated with Immunoglobulin Germline Gene Variation of Transitional B Cells. , 2022, 14, 84-93.		1
409	EBV dUTPase: A Novel Modulator of Inflammation and the Tumor Microenvironment in EBV-Associated Malignancies. <i>Cancers</i> , 2023, 15, 855.	1.7	0
410	Immunoglobulin <sc>GM</sc> ( <sup>13</sup> marker) genes as effect modifiers of <sc>Epsteinâ€Barr</sc> virusâ€multiple sclerosis association. <i>Immunology</i> , 0, , .	2.0	0
411	COVID-19, SARS-CoV-2 Vaccination, and Human Herpesviruses Infections. <i>Vaccines</i> , 2023, 11, 232.	2.1	4
412	Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond. <i>HemaSphere</i> , 2023, 7, e809.	1.2	5
413	Delivery Route Considerations for Designing Antigenâ€Specific Biomaterial Strategies to Combat Autoimmunity. <i>Advanced NanoBiomed Research</i> , 2023, 3, .	1.7	5
414	<sc>RNA</sc>â€binding proteins in autoimmunity: From genetics to molecular biology. <i>Wiley Interdisciplinary Reviews RNA</i> , 2023, 14, .	3.2	5
416	The adaptation model of immunity: A new insight into aetiology and treatment of multiple sclerosis. <i>Scandinavian Journal of Immunology</i> , 2023, 97, .	1.3	1
417	Contribution of Intravital Neuroimaging to Study Animal Models of Multiple Sclerosis. <i>Neurotherapeutics</i> , 2023, 20, 22-38.	2.1	2
418	Graph-Based Analysis of Brain Connectivity in Multiple Sclerosis Using Functional MRI: A Systematic Review. <i>Brain Sciences</i> , 2023, 13, 246.	1.1	3
419	Editorial: Environmental factors influencing the immune functions during multiple sclerosis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
420	Roadmap for understanding mechanisms on how Epsteinâ€Barr virus triggers multiple sclerosis and for translating these discoveries in clinical trials. <i>Clinical and Translational Immunology</i> , 2023, 12, .	1.7	4
421	Adoptive Tâ€cell therapy targeting Epsteinâ€Barr virus as a treatment for multiple sclerosis. <i>Clinical and Translational Immunology</i> , 2023, 12, .	1.7	9
422	Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
423	Preserving the brain: forum on neurodegenerative diseases. <i>Neurological Sciences</i> , 0, , .	0.9	0
424	Potential biological contributors to the sex difference in multiple sclerosis progression. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3

#	ARTICLE	IF	CITATIONS
425	Neuroimmunological Disorders. <i>Neurologic Clinics</i> , 2023, 41, 315-330.	0.8	2
426	Chronic effects of inflammation on tauopathies. <i>Lancet Neurology</i> , The, 2023, 22, 430-442.	4.9	12
427	Milk polar lipids: Untapped potential for pharmaceuticals and nutraceuticals. <i>PharmaNutrition</i> , 2023, 24, 100335.	0.8	2
428	UV radiation and air pollution as drivers of major autoimmune conditions. <i>Environmental Research</i> , 2023, 224, 115449.	3.7	2
431	Design principles of microparticle size and immunomodulatory factor formulation dictate antigen-specific amelioration of multiple sclerosis in a mouse model. <i>Biomaterials</i> , 2023, 294, 122001.	5.7	1
432	Interferon $\beta$ 1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 70, 104530.	0.9	1
433	Observed associations between indicators of socioeconomic status and risk of multiple sclerosis in Sweden are explained by a few lifestyle-related factors. <i>European Journal of Neurology</i> , 2023, 30, 1001-1013.	1.7	2
434	Tissue-resident memory T cells in the multiple sclerosis brain and their relationship to Epstein-Barr virus infected B cells. <i>Journal of Neuroimmunology</i> , 2023, 376, 578036.	1.1	4
435	The role of platelets in immune-mediated inflammatory diseases. <i>Nature Reviews Immunology</i> , 2023, 23, 495-510.	10.6	23
436	Clinically Manifest Infections Do Not Increase the Relapse Risk in People with Multiple Sclerosis Treated with Disease-Modifying Therapies: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 1023.	1.0	2
437	Immunologic prediction of long COVID. <i>Nature Immunology</i> , 2023, 24, 207-208.	7.0	3
438	Impact of Misdiagnosis in Case-Control Studies of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. <i>Diagnostics</i> , 2023, 13, 531.	1.3	2
440	How does neurovascular unit dysfunction contribute to multiple sclerosis?. <i>Neurobiology of Disease</i> , 2023, 178, 106028.	2.1	15
441	Decreased frequency of regulatory T cells and level of helios gene expression in secondary progressive multiple sclerosis patients: Evidence about the development of multiple sclerosis. <i>International Immunopharmacology</i> , 2023, 116, 109797.	1.7	0
442	Mendelian randomisation identifies priority groups for prophylactic EBV vaccination. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	0
443	Women in the field of multiple sclerosis: How they contributed to paradigm shifts. <i>Frontiers in Molecular Neuroscience</i> , 0, 16, .	1.4	1
444	A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. <i>EBioMedicine</i> , 2023, 89, 104456.	2.7	6
445	Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare Workers. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	6

#	ARTICLE	IF	CITATIONS
446	Barrier-to-autointegration factor 1 promotes gammaherpesvirus reactivation from latency. <i>Nature Communications</i> , 2023, 14, .	5.8	2
447	Role of DAMPs and cell death in autoimmune diseases: the example of multiple sclerosis. <i>Genes and Immunity</i> , 2023, 24, 57-70.	2.2	3
448	Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy. <i>Lancet Neurology</i> , The, 2023, 22, 338-349.	4.9	31
449	Can we predict T cell specificity with digital biology and machine learning?. <i>Nature Reviews Immunology</i> , 2023, 23, 511-521.	10.6	44
450	Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. <i>Nature Reviews Neurology</i> , 2023, 19, 160-171.	4.9	48
451	mRNA vaccines: The future of prevention of viral infections?. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	24
452	Infection induces tissue-resident memory NK cells that safeguard tissue health. <i>Immunity</i> , 2023, 56, 531-546.e6.	6.6	12
453	Different risk factors distinguish myalgic encephalomyelitis/chronic fatigue syndrome from severe fatigue. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
454	RNA polymerase II-associated proteins reveal pathways affected in VCP-related amyotrophic lateral sclerosis. <i>Brain</i> , 2023, 146, 2547-2556.	3.7	4
455	Gut virome-colonising <i>Orthohepadnavirus</i> genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation <i>in vivo</i> . <i>Gut</i> , 2023, 72, 1838-1847.	6.1	9
456	Early-life peripheral infections reprogram retinal microglia and aggravate neovascular age-related macular degeneration in later life. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	2
457	Learning from the nexus of autoimmunity and cancer. <i>Immunity</i> , 2023, 56, 256-271.	6.6	4
458	Myopia in late adolescence and subsequent multiple sclerosis among men. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 71, 104577.	0.9	0
459	Adrenoceptors as potential target for add-on immunomodulatory therapy in multiple sclerosis. , 2023, 243, 108358.		2
460	Human brain organoids to explore SARS-CoV-2-induced effects on the central nervous system. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	7
461	Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2023, 10, e200093.	3.1	1
463	Lessons from immunotherapies in multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 293-311.	1.0	0
464	Editorial: Current research on serological analyses of infectious diseases. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2



#	ARTICLE	IF	CITATIONS
465	Origins and immunopathogenesis of autoimmune central nervous system disorders. <i>Nature Reviews Neurology</i> , 2023, 19, 172-190.	4.9	9
466	Advances in Neurodegenerative Diseases. <i>Journal of Clinical Medicine</i> , 2023, 12, 1709.	1.0	22
467	Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets. <i>Pharmaceutics</i> , 2023, 15, 728.	2.0	3
468	COVID-19 and Multiple Sclerosis: A Complex Relationship Possibly Aggravated by Low Vitamin D Levels. <i>Cells</i> , 2023, 12, 684.	1.8	3
469	From bedside to bench: how existing therapies inform the relationship between Epstein-Barr virus and multiple sclerosis. <i>Clinical and Translational Immunology</i> , 2023, 12, .	1.7	4
470	Using The Virtual Brain to study the relationship between structural and functional connectivity in patients with multiple sclerosis: a multicenter study. <i>Cerebral Cortex</i> , 2023, 33, 7322-7334.	1.6	1
472	Citrullinated human and murine MOG35-55 display distinct biophysical and biochemical behavior. <i>Journal of Biological Chemistry</i> , 2023, 299, 103065.	1.6	0
473	Assessing the Efficacy of VLP-Based Vaccine against Epstein-Barr Virus Using a Rabbit Model. <i>Vaccines</i> , 2023, 11, 540.	2.1	1
474	Des objets essentiels à la théorie du Soi étendu: la coextension des champs par l'interdisciplinarité. <i>Revue Française De Psychosomatique</i> , 2023, n° 62, 133-150.	0.1	1
475	Epsilon toxin-producing <i>Clostridium perfringens</i> colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	9
476	How Does Vitamin D Affect Immune Cells Crosstalk in Autoimmune Diseases?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4689.	1.8	8
477	Virological Markers in Epstein-Barr Virus-Associated Diseases. <i>Viruses</i> , 2023, 15, 656.	1.5	7
478	Viral pathogens increase risk of neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2023, 19, 259-260.	4.9	8
479	Dozens of Infections Linked to Dementia and Other Neurodegenerative Diseases. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2023, 23, 12-13.	0.0	0
481	Coxsackievirus and Type 1 Diabetes: Diabetogenic Mechanisms and Implications for Prevention. <i>Endocrine Reviews</i> , 2023, 44, 737-751.	8.9	10
482	B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
483	DAMPs in Organ-Specific Autoimmune Diseases. , 2023, , 569-656.		0
484	Human genetic and immunological determinants of SARS-CoV-2 and Epstein-Barr virus diseases in childhood: Insightful contrasts. <i>Journal of Internal Medicine</i> , 2023, 294, 127-144.	2.7	0

#	ARTICLE	IF	CITATIONS
485	New insights into the treatment of meningoencephalomyelitis of unknown origin since 2009: A review of 671 cases. <i>Frontiers in Veterinary Science</i> , 0, 10, .	0.9	9
486	Repetitive elements in aging and neurodegeneration. <i>Trends in Genetics</i> , 2023, 39, 381-400.	2.9	9
487	The Role of Viral Infections in the Onset of Autoimmune Diseases. <i>Viruses</i> , 2023, 15, 782.	1.5	26
489	Beyond the amyloid hypothesis: how current research implicates autoimmunity in Alzheimer's disease pathogenesis. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2023, 60, 398-426.	2.7	3
490	Activated immune cells drive neurodegeneration in an Alzheimer's model. <i>Nature</i> , 2023, 615, 588-589.	13.7	2
491	Conference report: Advanced Therapies Week 2023. <i>Regenerative Medicine</i> , 2023, 18, 297-299.	0.8	0
492	Unmasking the tissue-resident eukaryotic DNA virome in humans. <i>Nucleic Acids Research</i> , 2023, 51, 3223-3239.	6.5	4
493	Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	15
494	Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents. <i>Trends in Microbiology</i> , 2023, 31, 788-804.	3.5	7
495	Inducible nitric oxide synthase deficiency promotes murine Î²-coronavirus induced demyelination. <i>Virology Journal</i> , 2023, 20, .	1.4	0
496	Autophagy pathways in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2023, 136, 103030.	3.0	14
497	Health outcomes of sensory hypersensitivities in myalgic encephalomyelitis/chronic fatigue syndrome and multiple sclerosis. <i>Psychology, Health and Medicine</i> , 2023, 28, 3052-3063.	1.3	0
498	In silico prioritisation of microRNA-associated common variants in multiple sclerosis. <i>Human Genomics</i> , 2023, 17, .	1.4	0
499	Virome-wide detection of natural infection events and the associated antibody dynamics using longitudinal highly-multiplexed serology. <i>Nature Communications</i> , 2023, 14, .	5.8	5
500	Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting. <i>Cell</i> , 2023, 186, 1309-1327.	13.5	40
501	Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes. <i>Communications Biology</i> , 2023, 6, .	2.0	4
502	The innate and T-cell mediated immune response during acute and chronic gammaherpesvirus infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	5
503	DNA Fragility and Repair, Some Personal Recollections. <i>Annual Review of Biochemistry</i> , 2023, 92, .	5.0	0

#	ARTICLE	IF	CITATIONS
504	Magnetic resonance imaging approaches for studying mouse models of multiple sclerosis: A mini review. <i>Journal of Neuroscience Research</i> , 2023, 101, 1259-1274.	1.3	1
505	The Heartâ€“Brain Interplay in Multiple Sclerosis from Pathophysiology to Clinical Practice: A Narrative Review. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 153.	0.8	0
506	EBV and Lymphomagenesis. <i>Cancers</i> , 2023, 15, 2133.	1.7	11
507	Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis. <i>Brain Communications</i> , 2023, 5, .	1.5	0
508	Multiple Sclerosis: A Review with a Focus on the Middle East and North Africa Region. , 2023, , 1-22.		0
509	Rethinking human cytomegalovirus latency reservoir. <i>Annals of the New York Academy of Sciences</i> , 2023, 1524, 30-36.	1.8	3
510	Systemic immune derangements are shared across various CNS pathologies and reflect novel mechanisms of immune privilege. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.4	1
511	Inflammation and Epsteinâ€“Barr Virus at the Crossroads of Multiple Sclerosis and Post-Acute Sequelae of COVID-19 Infection. <i>Viruses</i> , 2023, 15, 949.	1.5	6
512	Epstein-Barr Virus and Multiple Sclerosis: A Convolutated Interaction and the Opportunity to Unravel Predictive Biomarkers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7407.	1.8	1
513	Chronic and delayed neurological manifestations of persistent infections. <i>Current Opinion in Neurology</i> , 2023, 36, 198-206.	1.8	2
514	Perception of Quality of Life and Fatigue in Multiple Sclerosis Patients Treated with High-Dose Vitamin D. <i>Clinical and Translational Neuroscience</i> , 2023, 7, 12.	0.4	1
515	Central Nervous System Neuroimmunologic Complications of COVID-19. <i>Seminars in Neurology</i> , 0, , .	0.5	0
516	Molecular and cellular biology of multiple sclerosis. <i>Neurologie Pro Praxi</i> , 2023, 24, 140-144.	0.0	0
517	A clinical case of multiple sclerosis with an episode of schizophrenia-like syndrome. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2023, 123, 120.	0.1	0
546	Roles and regulation of microglia activity in multiple sclerosis: insights from animal models. <i>Nature Reviews Neuroscience</i> , 2023, 24, 397-415.	4.9	10
559	T cells in health and disease. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	36
563	Associations and interactions with herpesviruses and parasites (helminths) in people with multiple sclerosis. , 2023, , 89-103.		0
564	Monoclonal antibodies in multiple sclerosis treatment. , 2023, , 191-207.		0

#	ARTICLE	IF	CITATIONS
570	Applications of single-cell RNA sequencing in drug discovery and development. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 496-520.	21.5	31
589	Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2023, 19, 461-476.	4.9	2
594	Gut Microbiota Links With Disease. , 2023, , 105-145.		0
601	Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review. <i>Neurology and Therapy</i> , 0, , .	1.4	1
605	The immunology of long COVID. <i>Nature Reviews Immunology</i> , 2023, 23, 618-634.	10.6	70
607	Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	5
616	Multiple Sclerosis Diagnosis Pathways: An Intersectional Feminist Disability Life Course Perspective. <i>Research in Social Science and Disability</i> , 2023, , 29-47.	0.1	0
627	Biological and functional multimorbidityâ€™from mechanisms to management. <i>Nature Medicine</i> , 2023, 29, 1649-1657.	15.2	9
628	Shared Pathogenicity Features and Sequences between EBV, SARS-CoV-2, and HLA Class I Molecule-binding Motifs with a Potential Role in Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 0, , .	2.9	1
648	SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). <i>Nature Immunology</i> , 2023, 24, 1616-1627.	7.0	32
682	Multiple sclerosis: Motor dysfunction. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 119-147.	1.0	2
713	Ein perfekter Zufall. , 2023, , 109-124.		0
719	20.ÂNeurological Disorders. , 2023, , .		0
724	Vitamin D and the epidemiology of multiple sclerosis. , 2024, , 1167-1184.		0
741	The elusive nature of the oligoclonal bands in multiple sclerosis. <i>Journal of Neurology</i> , 2024, 271, 116-124.	1.8	0
765	Implication of Oxysterols and Phytosterols in Aging and Human Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2024, , 231-260.	0.8	2
767	Peripheral immune function and Alzheimerâ€™s disease: a living systematic review and critical appraisal. <i>Molecular Psychiatry</i> , 0, , .	4.1	0
776	Immunological Aspects of Reactivation of Latent Infections in Space Flight and Antarctica. <i>Human Physiology</i> , 2023, 49, 682-698.	0.1	0

#	ARTICLE	IF	CITATIONS
777	Chance, ignorance, and the paradoxes of cancer: Richard Peto on developing preventative strategies under uncertainty. <i>European Journal of Epidemiology</i> , 0, , .	2.5	0
782	Secrets and lies of host-microbial interactions: MHC restriction and trans-regulation of T cell trafficking conceal the role of microbial agents on the edge between health and multifactorial/complex diseases. <i>Cellular and Molecular Life Sciences</i> , 2024, 81, .	2.4	0
787	Ancient DNA reveals evolutionary origins of autoimmune diseases. <i>Nature Reviews Immunology</i> , 2024, 24, 85-86.	10.6	0
793	Epigenetics and multiple sclerosis. , 2024, , 183-223.		0
798	Editorial: Epstein-Barr Virus and multiple sclerosis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
818	Neuroprotection induced by coumarins in central nervous system disease models. , 2024, , 1411-1440.		0
819	<i>Helicobacter pylori</i> infection and risk of multiple sclerosis: an updated meta-analysis. <i>Neurological Sciences</i> , 0, , .	0.9	2
821	Multiple Sklerose. , 2024, , 69-84.		0
823	<i>Mycobacterium avium</i> ss. paratuberculosis and Human Disease: Bridging Infection and Autoimmunity. , 2024, , 559-581.		0
831	Introductory Chapter: State-of-the-Art Developments in Multiple Sclerosis. , 0, , .		0
832	Therapeutic Targeting of B Cells and Plasma Cells with a Focus on Multiple Sclerosis and Other Autoimmune Conditions. , 2024, , 425-435.		0
833	Epidemiology, epigenetics, and etiological factors in multiple sclerosis. , 2024, , 67-96.		0
834	Introduction to multiple sclerosis. , 2024, , 1-33.		0
853	Microbiota-brain interactions in aging and neurodegeneration. , 2024, , 175-193.		0
856	mRNA-based In Silico Vaccine Design using Epstein-Barr Virus'Envelope Glycoprotein GP350 and Glycoprotein BDLF3 through Immunoinformatics Approaches. , 2023, , .		0
865	Vitamin D and viral infections: Infectious diseases, autoimmune diseases, and cancers. <i>Advances in Food and Nutrition Research</i> , 2024, , .	1.5	0
869	Stem Cells from Dental Pulp of Deciduous Teeth: Twenty Years of Experience. , 0, , .		0